Risk analysis of the use of Cannabinoids compounds as therapy in Dementia

Background: Nowadays dementia pharmaceutical treatment has an unfavourable risk-benefit relation. New therapeutic approaches’ adoption is need due to the high prevalence of this condition. Objective: To evaluate the risk of using cannabinoids compounds as nonharmful therapeutic approach in dementia. Methods: A systematic literature review based on PRISMA was performed. PubMed and Clinical Trials database were used to collect articles between 2012 and 2022. Cochrane and Consort instruments were used to evaluate the methodology quality and report quality of adverse effects. Results: Tetrahydrocannabinol and Nabilone were associated to a moderate effectiveness in the symptomatology related with Dementia and to favourable safety and tolerability profiles. Contributions for evidence-based care: Evidence obtained shows the importance of these two compounds as a new approach to dementia treatment.